Please ensure Javascript is enabled for purposes of website accessibility

Why Intercept Pharmaceuticals Shares Soared Today

By Todd Campbell - Jan 30, 2015 at 10:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Intercept Pharma has received breakthrough therapy status for OCA as a treatment for the liver disease NASH.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Intercept Pharmaceuticals (ICPT 0.24%) soared by 16% today after the company announced that the FDA had awarded its clinical stage drug obeticholic acid breakthrough therapy designation as a treatment for nonalcoholic steatohepatitis, or NASH.

So What: NASH is a common liver disease that features a high level of fat in the liver, inflammation, and liver damage. NASH can cause liver cirrhosis or permanent liver damage that could require liver transplant in up to 10% of NASH patients.

The National Institutes of Health estimate that NASH affects between 2% and 5% of the American population and that it is one of the major causes of liver transplant behind hepatitis C and alcoholism. Unfortunately, the number of diagnosed cases of NASH is increasing, perhaps as a result of a doubling in adult obesity rates over the past 10 years. As a result, there's a significant need for new NASH treatment options.

Now what: Breakthrough designation means that Intercept can work more closely with the FDA on trial design and a future FDA application for approval. It also provides Intercept with the potential for a rolling review of its application prior to final phase 3 data results becoming available, as well as priority review. Overall, the awarding of breakthrough status could mean that Intercept is able to commercialize OCA more quickly than it would be able to otherwise.

The company is currently designing its phase 3 trial of OCA for NASH, but its phase 2b trial was halted early (a good sign) when independent regulators determined that OCA significantly decreased an important activity score by at least two points, without patients' scarring worsening compared to placebo. 

Given those mid stage trial results and the fact that breakthrough designation may mean that Intercept has an opportunity to usher OCA more quickly to market, investors should watch this company's progress closely. After all, the market for hepatitis C treatment, which also affects the liver, is worth billions of dollars annually (and growing), and that suggests that the market opportunity for NASH could prove to be similar. 

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E. B. Capital's clients may or may not have positions in the companies mentioned. Legal beagles won't let me ask them or let them tell me. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intercept Pharmaceuticals Stock Quote
Intercept Pharmaceuticals
$16.70 (0.24%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.